Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data

Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster

TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) --  Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology ("ASCO") to be held in Chicago from May 31 – June 4, 2024.

The oral podium presentation will include new clinical data from the ongoing Phase 1/2 ABILITY-1 Study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist, as both a monotherapy and in combination with pembrolizumab (KEYTRUDA) in patients with advanced or metastatic solid tumors.

Details of the podium presentation are as follows:

Title: “Results from ABILITY-1 Monotherapy Dose Escalation Study with MDNA11, an Engineered Long-acting IL-2 agonist, in patients with advanced solid tumors”
Abstract #: 2508
Abstract Session: Developmental Therapeutics – Immunotherapy
Date and Time: June 3, 2024; 11:30 AM-2:30 PM CDT
Presenter: Dr Victoria G. Atkinson, MBBS, FRACP, Gallipoli Medical Research Foundation, Greenslopes Private Hospital, and Princess Alexandra Hospital, University of Queensland, Australia.

The second abstract will provide new data analyses for bizaxofusp (formerly known as MDNA55) survival outcomes compared to a propensity matched external control arm (ECA) in nonresectable recurrent glioblastoma (rGBM).

Details of the poster presentation are as follows:

Title: "Phase 2 Study of Bizaxofusp, an IL-4R Targeted Toxin Payload, in Nonresectable Recurrent GBM: Comparison of Overall Survival with Contemporaneous Eligibility-Matched and Propensity Score Balanced External Control Arm"
Abstract #: 2709
Abstract Session: Poster Session – Central Nervous System Tumors
Date and Time: June 1, 2024; 9:00 AM-12:00 PM CDT
Presenter: Dr. John Sampson, MD, PhD, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery, School of Medicine, Duke University, Durham, North Carolina, USA

The full text of the published abstracts will be available on the 2024 ASCO Annual Meeting website on May 23^rd, 2024 at 5:00 PM EDT.